Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Nonquiescent "Idling" Population State in Drug-Treated, BRAF-Mutated Melanoma.

Biophysical journal - 27 Mar 2018

Paudel B Bishal, Harris Leonard A, Hardeman Keisha N, Abugable Arwa A, Hayford Corey E, Tyson Darren R, Quaranta Vito

Abstract excerpt

Targeted therapy is an effective standard of care in BRAF-mutated malignant melanoma. However, the duration of tumor remission varies unpredictably among patients, and relapse is almost inevitable. Here, we examine the responses of several BRAF-mutated melanoma cell lines (including isogenic subclones) to BRAF inhibitors. We observe complex response dynamics across cell lines, with short-term responses (<100 h)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epigenesis, Genetic

Share to BRAF gene

Share to Melanoma

Share to Molecular Targeted Therapy

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 29590606
DOI: 10.1016/j.bpj.2018.01.016
PMCID: PMC5883941

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Nonquiescent "Idling" Population State in Drug-Treated, BRAF-Mutated Melanoma.PMID 29590606Read ↗

Quantitative landscapes reveal trajectories of cell-state transitions associated with drug resistance in melanomaSemantic proximity Read ↗

Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance.Semantic proximity Read ↗

Multi-omic single-cell snapshots reveal multiple independent trajectories to drug tolerance in a melanoma cell lineSemantic proximity Read ↗

Trajectories from Snapshots: Integrated proteomic and metabolic single-cell assays reveal multiple independent adaptive responses to drug tolerance in a BRAF-mutant melanoma cell lineSemantic proximity Read ↗

Rapidly induced drug adaptation mediates escape from BRAF inhibition in single melanoma cellsSemantic proximity Read ↗

Growth rate-driven modelling suggests that phenotypic adaptation drives drug resistance in BRAFV600E-mutant melanoma.Semantic proximity Read ↗

Impacts of competition and phenotypic plasticity on the viability of adaptive therapySemantic proximity Read ↗

Impacts of competition and phenotypic plasticity on the viability of adaptive therapy.Semantic proximity Read ↗

Spatiotemporal profiling defines persistence and resistance dynamics during targeted treatment of melanomaSemantic proximity Read ↗

Dissecting targeted therapy resistance: Integrating models to quantify environment mediated drug resistanceSemantic proximity Read ↗

Understanding the potential benefits of adaptive therapy for metastatic melanomaSemantic proximity Read ↗

Receptor-Driven ERK Pulses Reconfigure MAPK Signaling and Enable Persistence of Drug-Adapted BRAF-Mutant Melanoma Cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.